TY - JOUR
T1 - Inflammasomes and intestinal inflammation
AU - Zmora, Niv
AU - Levy, M.
AU - Pevsner-Fischer, Meirav
AU - Elinav, Eran
N1 - Gilead Sciences International Research Scholars Program in Liver Disease; Abisch Frenkel Foundation for the Promotion of Life Sciences; Gurwin Family Fund for Scientific Research; Leona M. and Harry B. Helmsley Charitable Trust; Crown Endowment Fund for Immunological Research; Benoziyo Endowment Fund for the Advancement of Science; Adelis Foundation; French National Center for Scientific Research (CNRS); European Research Council, a Marie Curie Integration grant; German-Israeli Foundation for Scientific Research and Development; Israel Science Foundation; Minerva Foundation; Rising Tide Foundation; Helmholtz Foundation; European Foundation for the Study of Diabetes; estate of J. Gitlitz; estate of L. Hershkovich We thank the members of the Elinav lab for discussions and apologize for authors whose work was not cited because of space constraints. N.Z. is supported by the Gilead Sciences International Research Scholars Program in Liver Disease. E.E. is supported by Y. and R. Ungar, the Abisch Frenkel Foundation for the Promotion of Life Sciences, the Gurwin Family Fund for Scientific Research, the Leona M. and Harry B. Helmsley Charitable Trust, the Crown Endowment Fund for Immunological Research, the estate of J. Gitlitz, the estate of L. Hershkovich, the Benoziyo Endowment Fund for the Advancement of Science, the Adelis Foundation, J.L. and V. Schwartz, A. and G. Markovitz, A. and C. Adelson, the French National Center for Scientific Research (CNRS), D.L. Schwarz, the V. R. Schwartz Research Fellow Chair, L. Steinberg, J.N. Halpern, A. Edelheit, and by grants funded by the European Research Council, a Marie Curie Integration grant, the German-Israeli Foundation for Scientific Research and Development, the Israel Science Foundation, the Minerva Foundation, the Rising Tide Foundation, the Helmholtz Foundation, and the European Foundation for the Study of Diabetes. E.E. is the incumbent of the Rina Gudinski Career Development Chair and a senior fellow of the Canadian Institute For Advanced Research (CIFAR).
PY - 2017/7/1
Y1 - 2017/7/1
N2 - The inflammasome is a cytosolic multi-protein innate immune rheostat, sensing a variety of endogenous and environmental stimuli, and regulating homeostasis or damage control. In the gastrointestinal tract, inflammasomes orchestrate immune tolerance to microbial and potentially food-related signals or drive the initiation of inflammatory responses to invading pathogens. When inadequately regulated, intestinal inflammasome activation leads to a perpetuated inflammatory response leading to immune pathology and tissue damage. In this review, we present the main features of the predominant types of inflammasomes participating in intestinal homeostasis and inflammation. We then discuss current controversies and open questions related to their functions and implications in disease, highlighting how pathological inflammasome over-activation or impaired function impact gut homeostasis, the microbiome ecosystem, and the propensity to develop gut-associated diseases. Collectively, understanding of the molecular basis of intestinal inflammasome signaling may be translated into clinical manipulation of this fundamental pathway as a potential immune modulatory therapeutic intervention.
AB - The inflammasome is a cytosolic multi-protein innate immune rheostat, sensing a variety of endogenous and environmental stimuli, and regulating homeostasis or damage control. In the gastrointestinal tract, inflammasomes orchestrate immune tolerance to microbial and potentially food-related signals or drive the initiation of inflammatory responses to invading pathogens. When inadequately regulated, intestinal inflammasome activation leads to a perpetuated inflammatory response leading to immune pathology and tissue damage. In this review, we present the main features of the predominant types of inflammasomes participating in intestinal homeostasis and inflammation. We then discuss current controversies and open questions related to their functions and implications in disease, highlighting how pathological inflammasome over-activation or impaired function impact gut homeostasis, the microbiome ecosystem, and the propensity to develop gut-associated diseases. Collectively, understanding of the molecular basis of intestinal inflammasome signaling may be translated into clinical manipulation of this fundamental pathway as a potential immune modulatory therapeutic intervention.
UR - http://www.scopus.com/inward/record.url?scp=85020846957&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/mi.2017.19
DO - https://doi.org/10.1038/mi.2017.19
M3 - مقالة مرجعية
SN - 1933-0219
VL - 10
SP - 865
EP - 883
JO - Mucosal Immunology
JF - Mucosal Immunology
IS - 4
ER -